ViaCell, Pall get FDA clearance for sterile bag to store cord blood

By Elaine Rigoli

Tampa, Fla., April 25 - ViaCell, Inc. and Pall Corp. have received Food and Drug Administration clearance of a cord-blood collection bag suitable for use in a sterile field.

Pall and ViaCell collaborated on the development and design of the new collection bag.

ViaCell has exclusive rights to the new collection bag for family cord-blood banking and expects to introduce it as part of its ViaCord collection kit.

The sterile field bag will give families and their health care providers the ability to safely collect umbilical cord blood from newborns, even when born by cesarean section, the company said in a news release.

Umbilical cord blood is a valuable source of stem cells used to treat more than 40 diseases including a wide range of cancers, immune deficiencies and genetic disorders.

Pall, located in East Hills, N.Y., provides products in the biotechnology, pharmaceutical, transfusion medicine, semiconductor, water-purification, aerospace and industrial markets.

ViaCell, based in Cambridge, Mass., is a biotechnology company focused on enabling the widespread use of human cells as medicine.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.